Introduction: Alzheimer’s disease (AD) is a currently incurable neurodegenerative disorder that is defined by the buildup of amyloid beta peptide (Aβ) plaques in the brain. Herein, we aim to investigate two microRNA (miRNA), miR-106b and miR-153, for their ability to inhibit the synthesis of amyloid beta precursor protein. Since miR-106b and miR-153 are also deficient in AD patients, we hypothesize that increasing their concentrations in the brain will reduce plaque development, thereby ameliorating AD symptoms. Methods: Six groups of mice will be reared: a control group of healthy C57BL/6J mice; a control group of diseased B6. Cg-Tg(Thy1-APP)3Somm/J mice; 2 control groups of B6.Cg-Tg(Thy1-APP)3Somm/J mice, one treated an empty mini-osmotic pump, the other treated with functionless miRNA; and two treatment groups of B6.Cg-Tg(Thy1-APP)3Somm/J mice treated with miR-106b and miR-153 each. Then, a Morris water maze test and ELISA analysis will be conducted on each group to determine the effectiveness of the miRNA treatment at reducing Aβ plaque and AD symptoms. Discussion: As a proof of concept study, this experiment may determine whether miRNAs can alleviate AD symptoms and plaque development. There may be limitations regarding the applicability of murine models, as well as the implementation of induced AD in the genetically modified mice. The results of each experimental group will be compared using an ANOVA, and qualitatively for improvement of cognitive functioning. Conclusion: This experiment suggests an approach to counter the deleterious effects of AD. Future studies may investigate less invasive methods of administering miRNA treatments.
Introduction: Antifungal resistance (AFR) is an underrepresented issue that threatens both global health and food security. A common feature of many pathogenic fungi is their ability to produce RNA-induced silencing complexes (RISC) to protect against mycoviruses, thereby silencing the expression of targeted genes. Herein, we aim to create a genetically-modified mycovirus which can silence AFR genes specific to tebuconazole by leveraging the RISC silencing mechanism against the fungi’s native genes. Methods: To investigate the possible effects of mycoviruses on AFR, Fusarium graminearum (Fg) cultures will be infected with modified Fusarium graminearum deltaflexivirus 1 (mFgDFV1), each of which contain a 600 nt Fg ATP-binding cassette 3 (FgABC3) segment (an azole resistance gene). mFgDFV1 will be produced from Saccharomyces cerevisiae via an episomal plasmid and subsequently purified using an aqueous two-phase system. Thereafter, a Western and Northern blot will be employed to confirm successful mFgDFV1 synthesis. The efficacy of mFgDFV1 on repressing AFR will be evaluated by comparing the minimum inhibitory concentration (MIC50 and MIC90) of tebuconazole for Fg groups treated with mFgDFV1, wild-type FgDFV1, or no virus via protoplast fusion. Results: Upon completion of the experiments above, 3 sets of MIC50 and MIC90 values will be obtained. Each set will correspond to either mFgDFV1 treatment, wild-type FgDFV1 control, or water control. It is expected that Fg treated with mFgDFV1 will induce RISC, silencing FgABC3 and thus lowering MIC50 and MIC90 relative to both controls. Discussion: If effective, this approach to addressing AFR could be advantageous given the utility of RISC in fungi (e.g., if fungi downregulate the RISC response, they would become more susceptible to other viruses). Moreover, this method could be translated to a variety of other genetic and fungal targets if desired. Conclusion: This article presents a method to effectively overcome antifungal resistance by exploiting the fungal short interfering RNA defense mechanism. Should this experiment be successful, this modified Fg virus treatment could potentially stop multidrug-resistant Fg infestations, although further experimentation is required. Future studies could study the effectiveness of other antifungal resistant fungi and/or examine the biosafety and ecological footprint of this method
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.